Valeant 3Q Beat Has Not Swayed Wells Fargo from Sounding the Alarm


Valeant Pharmaceuticals (NYSE:VRX) has gotten some of the Street excited after a much-needed third quarter beat to re-ignite confidence after a string of litigations and investigations came to haunt the giant. Yet, what makes Wells Fargo analyst David Maris dismiss market enthusiasm as overblown?

Story Continues